Navigation Links
Thomson Reuters Examines Highly Cited Research in Bioterrorism
Date:5/18/2009

PHILADELPHIA and LONDON, May 18 /PRNewswire/ -- The Healthcare and Science business of Thomson Reuters today announced the results of a study assessing influential research in bioterrorism from 1999 to 2008. The findings appear in the May/June issue of Science Watch (www.sciencewatch.com) and are based on more than 12,000 bioterrorism-related papers published in Thomson Reuters-indexed journals during this time period.

Science Watch ranked the top 25 institutions by both total citations and citation impact (average citations per paper). The United States accounts for 23 of the top 25 institutions in both total citations and citation impact. The U. S. Army took the top spot in total citations with an impressive 9,637 citations to its researchers' work. The U. S. Centers for Disease Control and Prevention ranked second with 6,912 citations, and Johns Hopkins University with 5,006 citations ranked third.

U. S. institutions also led the pack in citation impact, a measure of average citations per published paper. The Institute for Genomic Research had an impact of 62.64 and the New York City Department of Health had an impact of 57.06. Claiming the third spot was the Imperial College of London with an impact of 31.55.

The most cited bioterrorism paper was published in 2001, regarding the causative agent of plague, Yersinia pestis; this paper has been cited nearly 500 times. The second most cited paper, entitled "Anthrax," was published two years before anthrax-tainted mail killed five people in 2001; this paper has now been cited more than 400 times. The third most-cited paper, published in 1999 and garnering more than 375 citations, discusses the use of smallpox as a biological weapon.

For the complete rankings of total citations and citation impact in the bioterrorism field, as well as a rundown of the most cited individual bioterrorism researchers during the time period, visit ScienceWatch.com.

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Thomson Reuters Commemorates World IP Week with Series of Strategic Intellectual Property Seminars Across the U.S.
2. APS Healthcare and Thomson Reuters to Manage New York States Medicaid Clinical Best Practices Review Program
3. Thomson Reuters Names Hottest Researchers and Papers of 2007-2008
4. Despite Decline in Share of Global Output, U.S. Science Impact Still Strong, Says Thomson Reuters
5. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
6. The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results
7. Thomson Reuters Launches New Biomarkers Solution
8. Thomson Scientific Begins Expansion of Web of Science
9. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
10. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
11. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... a United States multicenter, prospective clinical study that demonstrates the accuracy of ... capable of identifying clinically significant acute bacterial and viral respiratory tract infections ...
(Date:10/11/2017)... YORBA LINDA, CA (PRWEB) , ... October 11, ... ... adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and ... activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
Breaking Biology Technology:
(Date:7/20/2017)... -- Delta (NYSE: DAL ) customers now can use fingerprints ... Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National ... Delta,s biometric boarding pass experience that launched ... into the boarding process to allow eligible Delta SkyMiles Members who are ...
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( www.veratad.com ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
Breaking Biology News(10 mins):